Overview

Besifloxacin in Bacterial Keratitis

Status:
Unknown status
Trial end date:
2017-07-01
Target enrollment:
0
Participant gender:
All
Summary
This is a study comparing a new treatment for bacterial keratitis (also known as corneal ulcers) with the current standard of care. It is a randomized trial, and the investigators plan to test whether besifloxacin (a new antibiotic) in comparison to the current standard of treatment, fortified antibiotic drops (cefazolin and tobramycin).
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
McGill University Health Center
McGill University Health Centre/Research Institute of the McGill University Health Centre
Treatments:
7-(3-aminohexahydro-1H-azepin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
Besifloxacin
Cefazolin
Fluoroquinolones
Tobramycin
Criteria
Inclusion Criteria:

- • Provide signed and dated informed consent form

- Willing to comply with all study procedures and be available for the duration of
the study

- Male or female, aged 18 or older

- Clinically diagnosed bacterial keratitis, with any size ulcer > 1mm.

Exclusion Criteria:

- • Previously treated for current episode of bacterial keratitis with an antibiotic
drop

- Corneal Ulcers <1mm

- Known allergic reaction to components of the study products